MacroPore Biosurgery, Inc. Changes Name to Cytori Therapeutics, Inc.
"Over the past year, our adipose stem cell development efforts have resulted in numerous scientific, intellectual property, regulatory and financial milestones, which are representative of our transition to a biotechnology company," according to Christopher J. Calhoun, Chief Executive Officer of Cytori. "We look forward to building upon our recent success and advancing our adipose stem cell treatments into clinical trials in 2006."
As part of this strategic reorganization, MacroPore Biosurgery will become a division of Cytori. MacroPore Biosurgery will continue to manufacture the HYDROSORB(TM) family of FDA-cleared bioresorbable implants as well as continue the development of the Thin Film bioresorbable implants for Senko Medical Trading Co. in Japan. Cytori will report financials for MacroPore Biosurgery as a distinct business segment that will operate the bioresorbable implants business.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.